Skip to content

A Phase II study of induction chemotherapy with docetaxel, S-1 and cisplatin (DCS) for advanced gastric cancer with peritoneal metastasis (KUGC06)

A Phase II study of induction chemotherapy with docetaxel, S-1 and cisplatin (DCS) for advanced gastric cancer with peritoneal metastasis (KUGC06) - A phase II study of DCS chemotherapy for advanced gastric cancer with peritoneal metastasis(KUGC06)

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000004932
Enrollment
30
Registered
2011-03-01
Start date
2011-06-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric cancer with peritoneal metastasis

Interventions

Sponsors

Department of Surgery Graduate School of Medicine, Kyoto University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1)Pathologically confirmed gastric cancer 2)Gross or microscopic peritoneal metastasis confirmed by laparoscopy 3)No distant metastasis detected by CT or MRI 4)No previous treatment 5)Age between 20 and 75 years old 6ECOG 0 or 1 7)Capable of oral administration 8)Informed concent 9)Biology and biochemistry within normal limits

Exclusion criteria

Exclusion criteria: 1)Active bleeding from the tumor 2)Paralysis of intestine or ileus 3)Diarrhea(watery stool) 4)Synchronous multicancer 5)Serous infection 6)Interstitial pneumonitis or fibroid lung 7)Ascites requiring control or peritoneal metastasis detected by CT 8)Uncontrollable diabetes mellitus 9)Uncontrollable hypertention, heart insufficiency, myocardial infarction within 6 months,uncontrolled arrhythmia or angina 10)Patient who is pregnant or in lactation, or wish to become pregnant during this study.Male patient who intends to make someone pregnant during this study 11)Patient who has experienced serious drug allergy in the past 12)Patient with severe phyciatric disease 13)Patient who requires continuous use of flucytosine, phenytoin 14)HBsAb positive 15)Patient who is judged to be inappropriate as subject to this study by the principal investigator or the doctors in charge

Design outcomes

Primary

MeasureTime frame
R0 resection ratio

Countries

Japan

Contacts

Public ContactHiroshi Okabe

Graduate School of Medicine, Kyoto University Department of Surgery

hokabe@kuhp.kyoto-u.ac.jp075-366-7595

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026